GlassScriptPhysician profile
Katherine E Davis
NPI 1730298779
$605.29
in general payments reported to CMS, 2019-2025
17 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $163 · 2023: $20.97 · 2024: $62.63 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.84 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $129.25 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.59 | 2021-2022 | |
| Glaxosmithkline, LLC. | $42.27 | 2021 | |
| Pfizer INC. | $37.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.23 | 2022 | |
| Abbott Laboratories | $24.53 | 2025 | Amplatzer Talisman |
| Dexcom, INC. | $23.61 | 2021-2022 | |
| Amgen INC. | $23.55 | 2021 | |
| Lilly USA, LLC | $18.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.40 | 2021 | |
| Eisai INC. | $14.07 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2022 | |
| Mannkind Corporation | $13.01 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $11.81 | 2022 | |
| Genentech USA, INC. | $10.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.